Heterotopic Ossification: A Comprehensive Review by Meyers, Carolyn et al.
Heterotopic Ossification: A Comprehensive Review
Carolyn Meyers,1 Jeffrey Lisiecki,2 Sarah Miller,1 Adam Levin,3 Laura Fayad,4 Catherine Ding,5
Takashi Sono,1 Edward McCarthy,1 Benjamin Levi,2 and Aaron W James1,5
1Department of Pathology, Johns Hopkins University, Baltimore, MD, USA
2Department of Surgery, University of Michigan, Ann Arbor, MI, USA
3Department of Orthopaedic Surgery, Johns Hopkins University, Baltimore, MD, USA
4Department of Radiology, Johns Hopkins University, Baltimore, MD, USA
5UCLA and Orthopaedic Hospital Department of Orthopaedic Surgery and the Orthopaedic Hospital Research Center, Los Angeles, CA, USA
ABSTRACT
Heterotopic ossification (HO) is a diverse pathologic process, defined as the formation of extraskeletal bone in muscle and soft
tissues. HO can be conceptualized as a tissue repair process gone awry and is a common complication of trauma and surgery. This
comprehensive review seeks to synthesize the clinical, pathoetiologic, and basic biologic features of HO, including nongenetic and
genetic forms. First, the clinical features, radiographic appearance, histopathologic diagnosis, and current methods of treatment are
discussed. Next, current concepts regarding the mechanistic bases for HO are discussed, including the putative cell types responsible
for HO formation, the inflammatory milieu and other prerequisite “niche” factors for HO initiation and propagation, and currently
available animal models for the study of HO of this common and potentially devastating condition. © 2019 The Authors. JBMR Plus
published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
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Introduction
Heterotopic ossification (HO) is a diverse pathologic process,defined as the formation of extraskeletal bone in muscle
and soft tissues. The word “heterotopic” is derived from the
greek roots “hetero” and “topos,” meaning “other place.” HO can
be conceptualized as aberrant tissue repair and is increasingly
recognized as a common complication of trauma, surgery, and
other local or systemic insults. Nongenetic forms of HO are most
common, but rare genetic forms of HO also exist. The spectrum
of HO is broad. Some HO lesions may be small and clinically
irrelevant, while others may exact a high morbidity. HO is most
commonly incited upon tissue injury, followed by an influx of
inflammatory cells and subsequent downstream signaling
sequelae among predominantly resident cells of mesenchymal
origin. These downstream signaling events inappropriately
activate an osteogenic or osteochondrogenic program. In
practice, the designation of HO is applied to bone formation
at any extra-osseous site, including skeletal muscle, fascia,
tendon, ligament, subcutis, skin, vascular wall, or virtually any
site of connective tissue. Accompanying this anatomic/regional
heterogeneity, the cellular contributions to HO formation and
propagation are likewise diverse, made apparent by basic
research studies utilizing lineage-specific reporter animals. Even
the basic mechanisms of bone formation are nonhomogeneous
and may be either via intramembranous or endochondral
pathways. In the present comprehensive review, we seek to
synthesize the clinical, pathoetiologic, and basic biologic
features of HO to both present a unified description of the
current knowledge of HO and a reflection of its diversity in
presentation, in etiopathogenesis, and in ongoing research
efforts.
Clinical Features of Heterotopic Ossification
Epidemiology
The classic presentation of nongenetic HO is in young adults
with a clear history of local trauma or surgery.(1) Approximately
half of patients are in their second and third decades of life;
however, a broad age distribution is present from infancy to late
adulthood.(2–6) Men are slightly more commonly affected with a
sex ratio of 3:2. A history of trauma as the initiating event is
present in most cases (up to 75%),(2,4,6) and unrecognized or
“microtrauma” or repetitive mechanical stress is generally
thought to be present in the remaining patients.
HO is well documented to occur at increased frequency with
certain predisposing conditions, including orthopedic surgery,
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most commonly hip arthroplasty (occurs in up to 40% of
cases(7–9)), bone fracture or dislocation (occurs in up to 30% of
cases,(10) with elbow trauma or dislocation being a common site
of involvement(11)), high-energy extremity trauma,(12) traumatic
brain and spinal cord injury and other neurologic disorders
(occurs in up to 50% of spinal cord injuries(13)), and severe
burns (occurs in up to 20% of third-degree burns(14)). For
severe traumatic amputations, this incidence rises to above
90%(15)). These predisposing factors are discussed in more detail
below).
Clinical presentation
Nongenetic HO can occur nearly anywhere in the body, but the
most common areas include locations that are susceptible to
trauma, such as the elbow, thigh, pelvis, and shoulder.(16,17) The
head and neck is also a well-described location for traumatic
HO.(18,19) HO may occur in the skin, particularly in autoimmune
disorders such as dermatomyositis(20) and systemic sclerosis.(21)
The digits are also a well-described site for HO, in which case the
term “fibro-osseous pseudotumor of the digits” is also used.(22) A
spectrum of other distinctive reactive bony lesions of the hands
and feet are also well described (including florid reactive
periostitis, subungual exostosis, and bizarre parosteal osteo-
chondromatous proliferation). All have variably overlapping
histologic features with HO (see McCarthy and Sundaram(23) for
a review); however, these lesions are almost always associated
with the periosteum. As we will discuss, HO classically forms
without connection to the periosteum and can later fuse to the
periosteum as a secondary feature. Some anatomic sites are
relatively infrequently involved by HO (for example, the viscera
in both genetic and nongenetic HO,(24,25) or the diaphragm in
genetic forms of HO(24)). Understanding why these tissue sites
are relatively inhospitable to HO formation is an interesting and
unanswered question in the field.
The clinical presentation depends on the temporal stage of
nongenetic HO development. In the early/inflammatory phase,
HO presents with localized pain, tenderness, and swelling.
During this time, HO is often characterized by a rapid increase in
size, which may arouse clinical suspicion of a soft tissue
sarcoma.(5,16) In later stages and with gradual maturation of the
bone tissue, the swelling becomes more localized, firm, and
when adjacent to a joint may restrict motion. Lesions resembling
HO have been reported within nerves(26) or the abdominal
mesentery and fascia,(27) and their presentation is site specific. A
unifying theme of all locations is the presence of connective
tissue and thus of tissue sites that may contain stromal cells with
osteogenic potential.
The rare genetic causes of HO have a different presentation
and clinical severity than the far more common nongenetic
cases, and include fibrodysplasia ossificans progressiva (FOP)
and progressive osseous heteroplasia (POH). FOP is a rare, slowly
progressive disorder caused by ACVR1 mutations and initially
presenting in childhood(28–30) (OMIM:135100). Multiple congen-
ital skeletal malformations are associated with FOP, including
most frequently an abnormal first toe,(31) dysmorphologies
affecting the digits of the hand,(32) and malformations of the
cervical spine.(32) FOP patients eventually develop progressive,
painful flares and heterotopic lesions limiting mobility and
function. Biopsies should not be performed on FOP patients
because any surgical intervention leads to additional spread of
heterotopic lesions. Most cases arise from a spontaneous
mutation, but autosomal dominant transmission has also
been described.(32) FOP is characterized by progressive ossifica-
tion of muscle, tendon, aponeuroses, and ligaments. Ossifica-
tions generally develop from cranial to caudal and axial to
appendicular. Eventual peri-articular and soft tissue ossification
becomes so severe as to lead to difficulty with posture, gait, and
respiration.(24,33–35) Median age at death is approximately
40 years.(34,36) The mechanisms of ACVR1/ALK2 mutations
have been well documented, which includes the R206H
mutation resulting in hyperactive bone morphogenetic protein
(BMP) signaling and primarily endochondral ossification.(37–39)
Cells with the R206H mutation respond to Activin A with
increased SMAD1/5/8 phosphorylation comparison with wild-
type cells.(40) The bone formed is thought to occur through an
endochondral process based on human data and animal
models.
POH is a more recently characterized genetic form of
progressive HO caused by heterozygous inactivating mutations
in the GNAS1 gene.(41) POH is an autosomal dominant disorder
and can be a spontaneous/new mutation in the affected person
or paternal inheritance of the mutant allele (OMIM:166350).(41,42)
Ossification in POH has a predilection for the skin and subcutis
and appears to be primarily intramembranous, although
sporadic cartilage may also be found. The molecular defect
causing POH is the same as that causing pseudopseudohypo-
parathyroidism (PPHP) (OMIM: 612463),(43) which has a constel-
lation of physical findings referred to as Albright’s hereditary
osteodystrophy (AHO).(42)
Radiography
Radiographs are most often the first imaging study used to
detect nongenetic HO and often have distinctive features that
allow diagnosis. Unusual roentgenographic findings should
prompt a second imaging modality. In the early phases of HO, no
ossification can be found by radiographs.(44) The radiographic
appearance of HO is phasic and dynamic, which reflects the
sequence of changes reflecting bony maturation. The classic
appearance of mature intramuscular HO is that of a well-
developed and well-demarcated radiodense mass, with a zonal
ossification process (Fig. 1A, B). Here, radiodensity is most
apparent in the periphery of the lesion, imparting a calcified
outline or shell to the mass, also termed “eggshell calcification.”
Early lesions may have flocculent, irregular opacities without a
clear zonal maturation pattern. HO most often involves the soft
tissue only but may attach to the bone surface (also termed
parosteal HO). HO attachment to the underlying bone is usually
focal, but in longstanding lesions, a more broad-based bony
stalk to the underlying cortex may be found (Fig. 1C). In
parosteal HO, the periosteal reaction may obscure the classic
clinicopathologic presentation. In advanced stages, the HO may
be so massive as to cause complete ankylosis of the affected
joint (Fig. 1D). Several site-specific or disease-specific radio-
graphic features of HO are also notable and deserve special
mention. HO within tendons and ligaments has a distinctive
appearance on radiographs that often follows the anatomic
structure of the tissue (Fig. 1E). The differentiation of tendinous
calcification versus ossification by standard radiographs is not
reliable, as a pseudotrabeculation pattern may be visible with
calcification.(45) HO in dermatomyositis often has a distinct
roentgenographic appearance, with prominent stippled calci-
fications in clumped masses and sheetlike confluences.(46)
Distinct radiographic appearances in the rare genetic forms of
HO have also been described.(47) For example, radiographs of
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children with FOP generally show well-circumscribed areas of
deep HO that often corresponded to a distinct skeletal muscle
(Fig. 1F depicts more advanced ossification in FOP). In contrast,
radiographs of children with POH showed a “cocoon-like web” of
HO entangling the connective tissues from the dermis down to
the skeletal muscles.(47)
The appearance of HO by computed tomography (CT) is
usually characteristic, and the zonal maturation of the lesion
is well appreciated on CT.(23) Again, the imaging characteristics
of nongenetic HO in an intramuscular location are best
characterized. Early in HO progression, a low-density mass
may be the only sign of HO by CT. In such cases and if the
diagnosis of HO is suspected, short-interval follow-up CT
imaging is helpful in making the final diagnosis as peripheral
ossification develops. Cross-sectional imaging with CT is also
important in preoperative planning, by improving visualization
of the lesion’s relationship to important anatomic landmarks.(48)
By MRI, the appearance of HO is variable, depending on the
stage of maturation. Typically, HO is a well-defined mass with
heterogeneous signal, characteristically associated with diffuse
Fig. 1. Radiographic appearance of heterotopic ossification (HO). (A) Lateral radiograph of the knee, demonstrating a posterior, well-circumscribed soft
tissue mass with peripheral radiodensity characteristic of HO (white arrowhead). A history of blunt trauma to the area was provided. (B) Lateral
radiograph of the elbow, demonstrating an anterior, well-circumscribed, and heavily ossified soft tissue mass (white arrowhead). Peripheral radiodensity
is less apparent in this example. A history of antecedent local trauma was present. (C) Later, HO may form focal or even more diffuse connections to the
underlying bone. In this unusual case, a well-demarcated osseous lesion (red arrowhead) has a broad base of attachment (white arrowhead) to the
posterior aspect of the distal femur. This lesion came to clinical attention due to local discomfort but without a history of trauma. (D) In severe cases,
complete fusion (ankylosis) of the joint is observed, as is the case in the CT reconstruction with broad-based connections of bone from the proximal
femur to the ilium (white arrowheads). Clinical data not available. (E) Lateral radiograph of the ankle, demonstrating ossification of the Achilles tendon
(white arrowhead). A history of local trauma was provided. (F) In this case of genetic heterotopic bone (fibrodysplasia ossificans progressiva), extensive
ossification (asterisks) is present within the subcutis, muscle, and deep soft tissue around the proximal femur.
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surrounding perilesional edema.(49) In the early phases, there
may be fluid-fluid levels due to the presence of hemorrhage.
Enhancement after contrast administration can occur centrally
in HO due to vascularity within the lesion, making the
differentiation from sarcoma challenging at times. However,
the developing zonal ossification pattern is important in
distinguishing HO from a sarcoma, as identified by correlative
radiograph or CT. As HO matures, rim enhancement after
contrast administration is the predominant feature of HO
lesions, which helps to differentiate HO from a soft-tissue
sarcoma.(50)
Several site-specific classification schemes exist to grade the
severity of HO, which are particularly relevant for peri-articular
HO. The Brooker scale classifies hip-associated HO into four
classes of ascending severity (I–IV), which are related to the
distance between HO and the hip joint.(7) The Hastings and
Graham classification scale for elbow joint–associated HO uses a
three-point functional scale (I–III) to define the degree of clinical
and radiographic severity.(51)
Alternative imaging modalities may also be of benefit in the
detection of HO. Positron emission tomography (PET) may
be combined with CT, either using radiolabeled fluoride (F18)
or radiolabeled glucose (FDG). F18 binds hydroxyapatite
and detects areas of bone formation, and may be useful in
the detection of nongenetic HO(52) and recently in the early
detection and monitoring of flare-ups in FOP.(53) FDG PET
localizes to areas of increased metabolic activity and inflamma-
tion, and increased FDG avidity (although nonspecific) has been
noted in cases of nongenetic HO.(54) Single-photon emission CT
(SPECT) is a potential imaging modality for early detection of HO
with potentially improved sensitivity.(54–56) Although operator
dependent, ultrasound can be used to detect HO especially in
spinal cord injury patients.(57,58) Raman spectroscopy is a novel
imaging technology that has the potential to define the extent
of HO earlier than currently available radiographic studies by
detecting mineralized collagen within tissues.(59) Near infrared
imaging and ultrasound imaging have also been described to
identify HO before radiographic detection.(60,61)
Pathology
Nongenetic HO is often designated by the tissue type it involves,
such as myositis ossificans when involving skeletal muscle, or
fasciitis ossificans when involving fascia. Myositis ossificans
is the most common term used among pathologists, although
this term is a misnomer when more broadly used to discuss HO
(as HO is neither specific to muscle nor involves prominent
inflammation after its early stages). Nevertheless, the term
myositis ossificans is still commonly used. The histopathologic
appearance of HO evolves over time (Fig. 2). The histopathologic
features of nongenetic HO within an intramuscular location are
most well described and are summarized below.(62) A discussion
of how the histopathology of HO differs based on other
common tissues of origin, as well as differences between genetic
and nongenetic HO, is described in subsequent paragraphs.
Early lesions are often hypercellular and with little bone matrix,
and can prompt concern for a soft-tissue sarcoma. Later lesions
have prominent bone formation with a characteristic zonal
architecture that is best appreciated a low magnification (Fig. 2).
This zonal architecture with a predominant peripheral ossifica-
tion is a hallmark of HO. Early lesions demonstrate a hyper-
cellular proliferation of spindle cells often with little bone matrix
(Fig. 3A, B). Spindled areas often have features of “nodular
fasciitis” or “granulation tissue,” including high numbers of
normal mitotic figures, scattered multinucleated giant cells,
scattered inflammatory cells, and extravasated red blood cells.
As ossification ensues, woven bone with prominent osteoblastic
cell lining is characteristic (arrowheads, Fig. 3A). A gradual
continuum of woven bone to more mature lamellar bone is
often found, one helpful feature to distinguish HO from
extraskeletal osteosarcoma (Fig. 3C). HO is well circumscribed,
with a surrounding fibrous pseudocapsule often with thick-
walled blood vessels (Fig. 3D).(63) More mature lesions resemble
native bone elements, including thickened trabeculae of
lamellar bone with central fatty marrow and vascular spaces
resembling bone marrow sinusoids (Fig. 4A). The peripheral
aspects of mature HO may demonstrate compact bone tissue,
which resembles native cortical bone (Fig. 4B), sometimes
including histologic features reminiscent of Haversian systems
and Volkmann’s canals. Among nongenetic intramuscular HO,
metaplastic cartilage and endochondral ossification may be
found but are usually focal and may not be present (Fig. 4C). As
we will discuss in later paragraphs, HO lesions may demonstrate
more frank cartilage in a site-specific and disease-specific
manner. Other cases may demonstrate areas of dense, sclerotic
bone as found in an osteoma (Fig. 4D).
For the practicing pathologist, the most important diagnostic
distinction is between HO and extraskeletal osteosarcoma (OS).
Helpful histologic findings of HO include presence of bone
“maturation” and spatial zonation with more peripherally
mature bony elements.(63) The zonation phenomenon is most
conspicuous in lesions involving skeletal muscle (myositis
ossificans) and are less frequently found in nongenetic HO
involving fascia or the subcutis.(64) Importantly, the microscopic
features of immature bone trabeculae with osteoblastic rimming
and a progression to more mature bone are not found in
osteosarcoma.(65) As well, the absence of frankly sarcomatous
features is an important diagnostic distinction. HO does not
have obvious nuclear atypia or atypical mitotic figures.(66)
Occasionally HO with connection to the bone surface may pose
a diagnostic challenge to osteosarcomas that arise on the bone
surface (periosteal or parosteal OS(65)). Any challenging biopsy
that presents a diagnostic dilemma should be reviewed in the
context of clinical and radiographic findings, with a low
threshold for consultation.
Striking histologic similarity is present between fracture
healing and HO, which deserves special mention. Like early
fractures, early HO demonstrates a fibroproliferative stroma with
mitotic activity. Like fractures, bone formation is via a variable
combination of intramembranous and endochondral bone. As
HO matures, woven bone gives way to lamellar bone, which over
time is remodeled to develop a cortical appearance. Bone
marrow components are recruited into intervening bony
elements of HO and gives rise to the normal elements of
bone marrow, including a multilineage marrow, adipocytes, and
osteoclasts. As bone maturation occurs, so too does the
vasculature within HO develop and mature. Capillary-like vessels
in early HO lesions, also found in granulation tissue-like areas of
fractures, give rise to bone marrow sinusoid type vessels in
later HO.(63)
Ossification within tendons and ligaments have an over-
lapping but distinct histopathologic appearance from HO as
previously discussed.(67,68) Ossification within tendons may
occur within the tendinous body or the connection to the bone
(enthesis). The abnormal ossification of tendons, also termed
tenosynovial chondro-osseous metaplasia, can either follow
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acute trauma or chronic inflammatory insults (eg, spondyloar-
thritic ossification and “tendinitis”).(67,69) HO within tendons is
less frequently examined on a histopathologic level, as the
morbidity of tendon resection is high. Nevertheless, it seems
that endochondral ossification may be a more prominent
feature in tendinous HO than in classic intramuscular HO,(70–74)
although both intramembranous and endochondral tendon HO
have been reported.(72) This is not surprising given the well-
defined expression of the chondrogenic transcription factor
SOX9 within the entheses.(75) Foley and colleagues recently
reviewed the histologic features of peri-articular HO, and it
appears that an endochondral pathway is also a common and
distinguishing feature in this location.(76) These observations
are supported by animal studies that reproduce a robust
endochondral HO with tendinous injury.(77,78) Dystrophic
calcification is more commonly observed within HO of the
tendon or enthesis rather than intramuscularly (sometimes
termed calcifying tendinopathy), and calcification may be
admixed with ossification.(70,71,79) The “mature” bony lesions of
HO look essentially identical irrespective of their tissue location
of origin(68) and are essentially indistinguishable from normal
bony elements.
The basic pathways of bone formation in HO are somewhat
controversial and deserve special emphasis. Nongenetic HO can
form through both endochondral and intramembranous ossifi-
cation processes, and it is the authors’ opinion that a spectrum
exists within a given lesion from “endochondral-predominant”
HO in some cases to “intramembranous-predominant” HO in
others. Classic intramuscular HO (termed myositis ossificans),
which is biopsied early in its evolution, almost always shows
intramembranous rather than endochondral bone, and indeed
frank cartilage is rare.(1,23,62) In contrast and as discussed, Foley
and colleagues recently found cartilage and endochondral
ossification in all sampled cases of peri-articular HO.(80) Other
examples of tissue depot–specific variability exists as well, where,
for example, dermal HO may be more often intramembranous in
quality,(81) whereas tendon-associated HO in animal models(77) or
juxta-articular HO in human patients may be more often
endochondral.(80) This variability is compounded by the phasic
nature of HO, in which the cartilaginous template of endochon-
dral HO may be missed on biopsy or resection.
As previously alluded to, the rare genetic forms of HO do have
distinguishing histologic characteristics. FOP is a predominant
endochondral process,(82) and in the authors’ clinical experience,
Fig. 2. Histologic appearance of heterotopic ossification (HO) by H&E staining. (A) Whole-mount, tile scan image of early HO, demonstrating a highly
cellular lesion with multifocal areas of wispy osteoid formation. This enlarging intramuscular lesion was removed from the back of a 15-year-old patient,
with no known history of local trauma. (B) Representative central area, which demonstrates a “granulation tissue-like” spindle cell proliferation without
bone. Magnification 	40. (C) Representative peripheral area, demonstrating woven bone (arrowheads) and compressed fibrous pseudocapsule on the
lesions’ exterior (asterisk). Magnification 	40. (D) Mature HO, often received in fragments owing to the density of the bone tissue. Whole-mount, tile scan
image. Here, increased quantity of thickened, lamellar bone is observed. Longstanding intramuscular mass was excised from the forearm of a 31-year-old
patient. No history of trauma or other predisposing factor to HO was obtained in this case. (E) Representative central area, with lamellar bone trabeculae
with bone-lining cells (arrowheads) with intervening fibrous tissue resembling fibrotic marrow (asterisk). Magnification 	20. (F) Representative
peripheral area, with thickened lamellar bone bearing resemblance to native cortical bone. Magnification 	40. Red scale bars¼ 2 mm. Black
scale bars¼ 25mm.
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the amount of ossifying cartilage in FOP greatly exceeds that of
typical nongenetic HO. In contrast, POH is a predominant
intramembranous process with sporadic foci of frank cartilage
observed in some cases.(83) Whether the intramembranous-
predominant process in POH is owing to the common dermal
location or rather the underlying molecular etiology remains
unclear. Dystrophic calcification (DC) leading to ossification is
a third potential mechanisms for HO. Human evidence for
this transition or mixture of DC and HO has been described in
tendinous HO(70,71,79) and in dermatomyositis (where abundant
DC is often mixed with HO).(20)
Clinical risk factors: mechanism of injury
Hip arthroplasty
After total hip arthroplasty (THA), between 2% and 7% of
patients develop extensive periarticular HO(84) (Fig. 5A). In fact,
when all severities of ossification are included, HO may occur at
up to 40% post arthroplasty.(7–9) This is even more common in
secondary hip replacements. Patients with ankylosing spondyli-
tis, Paget’s disease, and hypertrophic osteoarthritis are at risk of
developing HO post arthroplasty.(85) Certain surgical factors
also predispose to HO post arthroplasty, including extended
ischemia time, use of cemented implants, and type of
approach.(86) In general, minimally invasive surgery (MIS)
approaches (such as MIS anterolateral [MIS-AL] and minimally
invasive direct anterior approach [AMIS]) are thought to carry a
lower risk of HO than the standard modified anterolateral
(STD-Watson-Jones) approach.(87) However, only a few studies
have been done relating surgical approach to HO, and whether
MIS approaches are more effective than transgluteal STD-Bauer
approach is still unknown.(87,88) Surgeons who perform a
posterior approach may resect the gluteus minimus to decrease
risk of HO.(89)
Fractures
The formation of heterotopic ossification after orthopedic
trauma has been studied most extensively in the setting of
acetabular fractures and elbow fractures. Heterotopic ossifica-
tion occurs in approximately 40% of patients after operative
fixation of an acetabular fracture.(90) The surgical approach can
impact the risk for heterotopic ossification, possibly related to
the amount of operative soft tissue damage.(91) More than 20%
Fig. 3. Histologic appearance of early/evolving heterotopic ossification (HO) by H&E staining. (A) The lesion is highly cellular and composed of
spindle cells and scattered inflammatory cells. In the upper right, heterotopic bone formation is observed, with prominent osteoblast rimming
(arrowheads). Note the intramembranous origin of bone in this case, which forms directly from stromal cell condensates. Magnification 	10.
(B) Higher magnifications demonstrate the spindle cell proliferation in areas without bone formation. A cellular proliferation of spindled to ovoid
cells are set in a variably edematous to fibrous stroma, with slender and elongated capillary-type vessels (arrowheads) and a background of
inflammatory cells (circles). No frank nuclear atypia or atypical mitotic figures are found. Magnification 	40. (C) A gradual continuum of woven bone
(left) to more mature lamellar bone (right) is often observed in cases of nongenetic HO, which in an extraskeletal location is pathognomonic for HO.
Magnification 	4. (D) Prominent bone lining osteoblasts are found (black arrowheads) in this example of HO. Also present in this image is the fibrous
capsule around the periphery of the lesion (lower right), which often houses thick-walled feeder vessels (red arrowhead). Magnification 	10.
Images from parts A, B, and D are taken from the same case: a 6-year-old patient with an intramuscular pelvic mass and no additional clinical history.
Images from C are from a 12-year-old patient with an intramuscular paraspinal mass. No additional clinical history available. Black scale
bar¼ 100mm. Red scale bar¼ 25mm.
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Fig. 4. Histologic appearance of mature/late-stage heterotopic ossification HO by H&E staining. (A) Appearance of mature HO, with thickened peripheral
bone (black arrowheads), interior fatty marrow cavity (black asterisk), and foci of endochondral ossification (red arrowhead). (B) A neo-cortex develops
with elements resembling native cortical bone. Note an adipocyte-rich interior on the left-hand side of the image. (C) Focal metaplastic cartilage and
endochondral ossification within this case are present. (D) In less common instances, sclerotic bone may develop, as seen in an osteoma. Images from
A–C obtained from a 27-year-old patient with ossified soft tissue mass of the foot, with history of antecedent trauma; D obtained from a 66-year-old
patient with an ossified soft tissue mass of the foot. Antecedent trauma as well as a history of previous resections was provided. All prior resections
contained heterotopic bone. Red scale bars¼ 2 mm. Black scale bars¼ 50mm.
Fig. 5. Examples of HO post arthroplasty or spinal cord injury (neurogenic HO). (A) Flocculent radiodensity representing developing HO superior to
the greater trochanter (arrowhead) in a post-arthroplasty patient. (B) Massive and bilateral, peri-articular HO in an immobilized patient with spinal
cord injury.
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of those who develop HO in this setting have clinically relevant
range of motion deficits. Additional risk factors include
concomitant neurologic injury, delayed internal fixation, and
use of bone graft and/or bone-graft substitute. Animal models of
polytrauma-induced HO have been developed, which mimic
blast injury and/or major orthopedic intervention.(92)
Spinal cord and traumatic brain injuries
HO is well known to develop around joints after central
neurologic injury, including traumatic brain injury and spinal
cord injury (Fig. 5B). The incidence of neurogenic HO has been
reported to range from 10% to 53%.(13) Patients with low cervical
or high thoracic lesions are the most likely to develop this
complication.(93) Patients with severe spasticity, impaired
cognition, tracheostomy, pneumonia, and/or urinary tract
infections are at a higher risk.(93) Patients with neurogenic HO
develop lesions around larger joints.(23) HO after spinal cord
injury generally forms caudal to the level of injury, whereas HO
after closed TBI may occur around any large joint, including the
hip, knee, elbow, and shoulder.(94) Involvement of small joints by
neurogenic HO is rare.(23) Development of neurogenic HO
generally occurs within a few months after CNS injury and
progresses over a period of years.
Although the relationship between the nervous system and
the formation of bone remains incompletely understood, it is
known that peripheral neurotransmitters affect osteoblast
formation.(93,95) Animal studies that denervate bone have
resulted in significant alterations in bone metabolism and
healing. For example, sciatic nerve dissection reduces bone
growth and impairs fracture healing.(96,97) Similarly, mice treated
with the vanilloid capsaicin to chemically denervate sensory
nerves exhibited lower trabecular and cortical bone vol-
umes.(98,99) It is not yet clear how central nervous system insults
initiate a sequence of events that lead to juxta-articular HO.
Other contributing factors may include prolonged immobiliza-
tion, vascular stasis, edema, as well as the passive manipulation
of joints in immobilized patients. Nevertheless, animal models of
spinal cord injury–induced HO have been devised, which
incorporate a combination of spinal cord transection with
intramuscular insult.(100) Interestingly, the mechanism of
ossification in CNS injury models of HO has not been described,
and thus whether endochondral, intramembranous, or DC-rich
lesions are present is as yet unknown.
Thermal injury
HO is a well-recognized complication of burn injury, with
increasing risk of HO with increasing percentage of body surface
area affected.(101) Burns involving >20% of the body substan-
tially increase the likelihood of HO formation.(101) Additional risk
factors include male sex and full-thickness injury at or near a
joint.(101) Thermal injury–induced HO is similar to neurogenic HO
in that it occurs with striking predilection for the juxta-articular
regions. HO occurs with the highest frequency at the elbow,
followed by the shoulder, and subsequently the hip. Owing to its
location around joints, those patients with burn injury–induced
HO often have a restriction in the range of motion as an early
manifestation of the ossification. Among burn patients, it is
particularly important to distinguish juxta-articular HO from scar
contracture—both of which limit joint movement. Small animal
models to re-create burn injury–induced HO have been
developed (combined burnþ tenotomy model).(78)
Management
The potential management options for HO are best divided into
two categories: 1) prophylactic strategies to prevent or mitigate
the extent of HO, and 2) treatment strategies to improve
symptoms and function once the condition has occurred. Most
studies pertain to non-genetic HO, while specific treatments for
genetic forms of HO are also discussed. The distinction is often
determined by the presence or absence of HO at the time of
intervention, though there may be a period of overlap in the
early stages of ossification where the severity may be decreased.
In a survey of orthopedic and trauma centers in Germany,
two-thirds of respondents reported routine use of prophylaxis
against HO for high-risk injury patterns.(102)
Prophylactic strategies
Radiation therapy
Low-dose radiation has been studied both as a prophylactic
modality in HO occurrence (as primary prevention in high-risk
patients) or as a prophylactic modality in HO recurrence (as
secondary prevention together with surgical excision). The
prophylactic use of radiation therapy is best studied in the
context of hip arthroplasty. Of the randomized controlled trials
that have been performed, definitions of high-risk patients vary
but may include those patients with hypertrophic osteoarthritis,
ankylosing spondylitis, diffuse idiopathic skeletal hyperostosis,
or prior HO.(103) Thus, prophylaxis against HO occurrence (in
those at high risk) and HO recurrence (preexisting HO) are often
studied together. Prophylactic doses typically range from 400 to
800 cGy, and are given either 24 hours preoperatively or up to
72 hours postoperatively.(103) For patients undergoing total hip
arthroplasty, a single-center randomized trial suggests that
700 cGy given postoperatively was significantly more effective at
preventing HO (25%) than 400 cGy (42%)(104) given postopera-
tively. Higher doses, however, have not proven to be of
increased benefit for prevention.(105) Furthermore, there does
not appear to be a significant difference between preoperative
and postoperative radiation dosing regarding efficacy or
complications, with the exception that those treated more
than 8 hours preoperatively or more than 72 hours postopera-
tively may demonstrate a greater rate of radiographic ossifica-
tion after hip surgery.(105,106)
Although the majority of controlled studies have focused
upon patients undergoing surgery around the hip, the results
regarding prophylactic radiation have been extended to other
indications as well.(107) Among spinal cord injury patients with
evidence of early neurogenic HO, a single radiation fraction of
700 cGy limited the progression of ossification around the
hips.(108) After elbow trauma, however, the results are somewhat
less favorable, with limited evidence to support its routine
use.(109) A randomized controlled trial was stopped early
because of concerns over increased rates of nonunion in those
receiving 700 cGy of radiation after surgical management of
intra-articular elbow fractures.(110)
Among the concerns with the use of prophylactic radiation
are joint stiffness and potential oncogenesis. The relatively low
risk of joint stiffness after low-dose radiation can be weighed
against the decreased range of joint motion and potential
ankylosis that can develop with HO. Regarding oncogenesis, a
case-control analysis has failed to demonstrate a significantly
increased rate of malignancy in patients treated at this low dose
of radiation.(111) It bears noting, though, that the number of
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patients needed for adequate power is rarely met, and the
theoretical risk of malignancy remains.(112)
NSAIDs
Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the most
commonly utilized prophylaxis for HO.(102) Numerous NSAIDs
have demonstrated efficacy, though postoperative indometha-
cin has been the historical gold standard, traditionally dosed at
25 mg three times daily for up to 6 weeks after surgery.(113)
In comparison to single-dose radiation, indomethacin has
shown equal efficacy in preventing HO after total hip arthroplasty
and acetabular fracture surgery in high-risk individuals.(85,114)
However, the optimal NSAID duration and dosing regimen has
not been definitively proven.(94) Other studies have utilized
ibuprofen, diclofenac, and ketorolac, among others. More
recently, consideration has been given to the use of COX-2
selective inhibitors, due to concerns over gastrointestinal effects
with nonselective NSAIDs.(115) In a case-controlled study in total
hip arthroplasty, celecoxib demonstrated significant reduction in
the incidence of HO compared with untreated controls.(115) When
comparing COX-2 selective inhibitors with nonselective NSAIDs,
there does not appear to be a significant difference regarding
their efficacy, nor their dose-limiting toxicities over the short time
period of prophylactic use.(116)
Numerous studies have suggested that NSAIDs may prove
beneficial for indications unrelated to hip arthroplasty and
acetabular fracture surgery, including hip arthroscopy, elbow
trauma, and spinal cord injury.(117–119) Despite its relatively low
rate of complications, NSAID use has been associated with an
increased risk for nonunion of acetabular fractures.(90) Overall,
the utility of NSAIDs and radiation in preventing nongenetic HO
appear similar, though the cost associated with NSAID therapy is
typically markedly less.(120)
Other prophylactic modalities
Although not commonly used in nongenetic HO, corticosteroids
are used as a prophylactic modality in FOP patients. A brief course
of high-dose corticosteroids is often used in FOP patients within
the first 24 hours of flare-ups to reduce inflammation and tissue
edema observed in early stages of the disease.(24) However, the
use of corticosteroids in FOP patients is generally limited to
treating flare-ups in the major joints, the jaw, and submandibular
area. Corticosteroids are not used as a chronic treatment of FOP,
so as to limit side effects associated with long-term use.(121)
Despite early enthusiasm for the potential role of bisphosph-
onates in the prevention of neurogenic HO, further analysis has
failed to demonstrate a clear benefit for the use of these
medications in preventing HO.(122–124) In fact, there is some
indication that antiresorptive therapy may increase the risk of
developing HO, or may simply delay rather than prevent the
bone formation. Future therapeutic modalities such as retinoic
acid receptor (RARg) agonists(125) (discussed in more detail in
Signaling Pathways in HO below), as well as free-radical
scavengers(126) are currently under investigation, though their
clinical utility remains to be elucidated.
Treatment strategies
Physical therapy
It is unclear whether physical therapy plays a significant role in
the development or mitigation of HO, and conflicting thoughts
are reflected in the literature among burn and spinal cord
injury patients about early range-of-motion exercises.(94) For
patients with contusions to the thigh, a quadriceps stretching
regimen has been proposed as a method for improving the
time to return to full activity and potentially preventing
HO.(127) In the authors’ clinical experience, burn surgeons will
often comment on the increasing incidence of HO in those
patients who receive overly aggressive passive range-of-
motion exercises on the elbow in an attempt to prevent
skin contracture. Direct comparison trials are lacking, and the
applicability of stretching or range-of-motion exercises for
other risk factors for ossification are questionable. In patients
who have developed maturing HO, clinical management
differs based on clinician preferences. For example, many
recommend against passive exercises, which could exacerbate
inflammation and possibly HO, while others recommend a
physical therapy regimen to improve range of motion and limit
contractures.
Surgery
The natural history of HO is to fully ossify into mature bone over
time. Many patients with HO report pain, painful motion,
restricted motion, or prominent bone that can lead to pressure
sores or impaired hygiene. Although the focal discomfort may
improve after the inflammatory stage abates, patients with
persistent symptoms have few management options other than
operative intervention.(102) Patients without significant symp-
toms, however, can be managed nonoperatively.
Surgical resection for nongenetic HO is ideally performed
after the osseous maturation is complete, which is typically by
6 months after the initiation of HO. Excision before 6 months
may be associated with an increased risk of recurrence of HO.(128)
No additional benefit appears to exist with further delay in
operative management.(128–130) Although some have advocated
that excision should be performed early to prevent irreversible
loss of motion, a comparison between 18 patients with elbow
ankylosis and 27 patients with partial restriction of motion
demonstrated comparable return of motion.(131) Especially for
HO at specific anatomic sites (such as tendinous HO or
intraperitoneal HO), the benefits of removal must be weighed
against the morbidity of the surgical procedure itself. As
previously alluded to, surgical management in FOP is generally
not recommended because this may lead to additional spread of
heterotopic lesions.
Even though complete excision is not always practical or
possible, incomplete resection of the HO is associated with
recurrence.(128) Interposition of soft tissue is not of clear
benefit.(102) It is important to note that, unlike neoplastic
processes, HO does not always respect natural anatomic barriers
and may encase major neurovascular structures. This is perhaps
responsible for the high reported rates of neurovascular injury
after operative intervention in these patients.
Basic Biologic Features of Heterotopic
Ossification
Animal models of HO
Many models have been devised to study heterotopic ossifica-
tion. They can be roughly divided into those that mimic a
FOP-like phenotype via similar signaling cascades, those that
induce HO by causing trauma, and those that mimic neurogenic
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HO formation via spinal cord injury. Many traumatic models use
a combination of insults to generate significant HO.
Genetic models
Genetic models of HO formation typically replicate conditions
similar to FOP. There are two major FOP-like animal models of
HO with mutations in the Acvr1 (Alk2) receptor: the Alk2
R206H(132–134) and Alk2 Q207D(125,135) models. The Alk2 R206H
mutation is most commonly used and can reproduce HO with a
clinical presentation analogous to FOP.(132) With global expres-
sion of the mutant allele, HO spontaneously occurs in the
sternum, caudal vertebrae, hip joint, and hindlimb. As in human
FOP, lesions progressively ossify and eventually fuse to native
skeletal elements.(132) Depending on the particular driver, both
injury-dependent and non-injury-dependent models exist for
development of FOP-like lesions.(132,133) These serve as preclini-
cal tools and have been used for the ongoing development of
treatments for FOP. In addition to global Cre models of
Acvr1R206H, tissue-specific drivers of Cre have been studied
in FOP models and may be able to help determine cell types
responsible for HO.(133) These studies help support the putative
cell types responsible for FOP-like HO formation (discussed in
more depth in Cell Precursers of HO below).
Traumatic models
Trauma-induced animal models of HO have been developed.
Early attempts applied blunt-force trauma to muscle but had low
success rates. Models that combine insults have had more
consistent development of HO, such as blunt-force trauma and a
period of forced range of motion.(136) A model of hip surgery has
been developed in New Zealand white rabbits where an incision
is made over the greater trochanter and the medullary canal of
the femur is reamed out, leaving the bone reamings in the
wound. Intentionally causing muscle injury by performing
greater dissection, wider exposure, and clamping of the gluteus
muscles to induce ischemia increases HO formation relative to
minimal dissection and no clamping.(137,138) Another model of
traumatic HO formation also demonstrates the benefit of
multiple insults in causing consistent heterotopic bone forma-
tion. A mouse model demonstrates that 30% total body surface
area (TBSA) burn in conjunction with Achilles tenotomy
significantly increases heterotopic bone formation compared
with tenotomy or burn alone.(59)
BMP-induced models
Local injection or surgical implantation of BMPs and/or
mesenchymal progenitor cells expressing BMPs can be used
to induce HO formation.(139) A variety of vehicles can be used to
carry the BMPs, such as an injectable Matrigel or an implantable
collagen sponge. There are a variety of options for where to
implant the vehicle. Subcutaneous application is appealing for
its technical ease, the lack of confounding osteogenic
components in this space, and the space for implantation in
lax rodent skin.(136,140,141) Subcutaneous injection of BMPs in
Matrigel is commonly employed.(141) Impregnated Matrigel
solidifies in vivo to form a localized source of BMP ligand.(142)
Intramuscular injection(143) or implantation(144) is also a good
option for studying HO formation, although one must remove
the confounding factors of osteogenesis in host muscle stromal
cells and the upregulation of inflammatory and pro-osteogenic
signaling in response to the muscle injury itself.(145) Currently,
BMP-induced models rely widely on recombinant human
BMP2(142) but have also studied other BMP family members
including BMP4(146) and 9.(145) Kidney (infrarenal) capsule
implants can be used to study HO formation, although this is
less frequently done because of technical difficulty.(140)
Neurogenic and spinal cord injury models
A subset of the acquired or traumatic HO models, models of
neurogenic HO have been developed. One such model uses a
laminectomy and sharp transection of the spinal cord at the T7-8
level with concomitant muscle inflammation provoked by
injecting cardiotoxin into the hamstring muscle of the
mice.(100) This model again demonstrates the commonality of
multimodal injury for development of reliable HO in an
experimental setting.
Cell precursors of HO
Much has been learned from transgenic reporter animals to
identify the cell types putatively responsible for bone and
cartilage formation within HO. The data using transgenic
reporter mice will be the focus of this review (Tables 1 and 2),
although HO progenitor cell correlates have also been defined
by flow cytometry in mouse models.(147) Several caveats exist in
the interpretation of lineage tracing studies, including:
1) Animal models of HO have some substantive differences in
form of trauma, location of HO, and presence or absence of
specific genetic mutation, and so not all models of HO
would be expected to have the same cellular contributors.
2) Off-target Cre expression may occur when Cre is expressed
in cells or tissues not directly dictated by the promoter used
to drive Cre expression. Individual reporters are often more
broadly distributed than first reported.
3) Presence of the Cre transgene alone may result in cellular
toxicity and unintended phenotypes that may secondarily
impact the study of HO.
4) Some Cre strains demonstrate mosaic patterns of Cre
expression that can differ widely between littermates. For
example, this has been documented in Vav1-Cre line,(148)
which has been studied in HO.(149)
Table 1. Summary of Local Cell Types That Have Been Observed
to Directly Contribute to Murine HO Using Transgenic Reporter
Mice
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5) Additional potential drawbacks exist in the case of ligand-
dependent (eg, Cre-ERT system and tet-ON/tet-OFF
systems) reporter systems. For example, background Cre
activation in the absence of tamoxifen (leakiness) may
occur with variable frequency depending on the con-
struct. As well, the domain of reporter activity can be
influenced by the ligand administration schedule, includ-
ing the dose, route, and timing, as well as the chase
period.
6) Finally, injury models of HO may induce reporter activity in
an aberrant fashion in cells that natively do not normally
express the factor.
Nevertheless, the aggregate data suggest that the predomi-
nant source of HO is generally from local stromal/fibroblastic
cells of mesenchymal origin within the connective tissue
of skeletal muscle, fascia, and/or subcutis. This includes use of
Prx1-Cre,(150,151) Scx-Cre and Scx-CreERT2,(149,150) Mx1-Cre,(149)
NFATc1-Cre,(152) and Glast-CreERT(153) strains that all have
overlapping domains of distribution within reporter animals.
Other putative cell types that may contribute to HO genesis
include endoneurial cells highlighted by Wnt1-CreERT,(154)
pericytes and other perivascular cells also highlighted by
Glast-CreERT reporter animals,(153) and endothelium, which
has undergone endothelial-to-mesenchymal transition as
highlighted by the Tie2-Cre mouse strain (so-called
EndMT).(142,155) In the case of potential direct endothelial
contribution to HO, a mesenchymal population of Tie2þPdg-
fraþSca-1þ cells resident in skeletal muscle may also
represent the Tie2þ direct contribution to HO (and thus a
non-endothelial Tie2þ cell contributor may predominate).(156)
Several studies suggest that circulating mesenchymal cell
types also contribute to HO formation,(157–160) which are likely
nonhematopoietic in origin.(160) Conversely, studies in reporter
animals have suggested several cell types that likely do not
represent direct cellular precursors of ectopic bone and
cartilage in HO, including degenerating skeletal muscle
fibers, vascular smooth muscle, and chronic inflammatory
cells(142,149,161) (Table 2). Nevertheless, and given the diversity
of murine HO models, it is important to realize that which cell
types directly contribute to HO bone and cartilage and which
cell types represent requisite “niche” factors for HO genesis are
both still not clearly defined.
Inflammation and HO
In a simplistic conceptualization, inflammation is a key “niche
factor” for the development of HO and a commonality across
many of the conditions that predispose to HO formation. HO is
known to occur in autoimmune diseases such as limited
cutaneous systemic sclerosis,(21) dermatomyositis,(20) and
inflammatory arthritis.(162) Autoimmune diseases affecting the
nervous system have also been reported as predisposing factors
to HO, including anti-NMDA receptor encephalitis(163) and
Guillain-Barre syndrome.(164) The role of trauma-induced
inflammation as inciting bone formation is logical, as inflamma-
tion characterizes the early stages of fracture repair.(165) Use of
NSAIDs for traumatic HO prophylaxis, and steroids for FOP
treatment, rests on the theory that reducing postoperative
inflammation will likewise reduce HO formation.(166) Animal
studies have begun to elucidate the complex and multifaceted
role of the immune system in HO genesis and propagation.
Innate immunity and HO
Macrophages play an important role in endochondral ossification
and fracture repair. Existing research likewise implicates the
involvement of macrophages in several mouse models of HO(167)
and in human HO. Formation of HO in a BMP4 overexpression
model has been shown to be dependent on macrophages, as
macrophage depletion diminishes HO formation.(161) Likewise, in a
mouse model of neurogenic HO using spinal cord injury combined
with muscle injury, investigators identified macrophages in HO
tissue and determined that depletion of macrophages significantly
reduced HO formation.(100) This finding was reinforced in the Acvr1
R206H knock-in mouse model of FOP.(168) Macrophage infiltration
was observed to occur at early stages of HO lesion formation, and
macrophage depletion with Clodronate treatment reduced but
did not completely prevent HO formation in this study.(169)
However, the route of administration for Clodronate (intraperito-
neal versus intravenous) has different effects on monocytes, and it
remains to be seen if more effective mechanisms to target the
macrophage in HO can be developed. Accumulation of macro-
phages have likewise been observed in FOP patient samples.(169)
More lineage-specific depletion methods and characterization of
the monocyte subpopulations that traffic to the injury site are
needed. As well, the cargo delivered or paracrine activity of
macrophages in an HO setting have begun to be examined. For
example, in a mouse model of neurogenic HO caused by spinal
cord injury, Oncostatin M of macrophage origin was observed to
promote osteoblastic differentiation of precursor cells.(170) Thus,
though macrophage infiltration of the soft tissue and presumed
paracrine stimulation of HO formation is a consistent feature across
genetic, traumatic, and neurogenic models of HO, further studies
are needed to validate these findings.
Mast cell involvement in the pathogenesis of HO may also be
important. Increased mast cells have been documented in cases
of nongenetic HO, with mast cells appearing near sites of ectopic
bone formation upon biopsies of HO at various sites.(82)
Increased mast cell density may be an even more prominent
finding in FOP, with up to 150-fold greater mast cell density at
the periphery of FOP lesions compared with other inflammatory
myopathies.(171) Inhibition of mast cell degranulation can be
accomplished by administration of Cromolyn, an FDA-approved
drug for asthma. Cromolyn treatment significantly reduced
ectopic bone formation in a BMP2-indcued mouse model of
HO,(82) as well as the Acvr1 Q207D transgenic mouse model of
Table 2. Summary of Cell Types That Have Been Observed to Not
Directly Differentiate Into Ectopic Bone and Cartilage in Murine
HO Using Transgenic Reporter Mice








SM22a-Cre Vascular smooth muscle/pericyte(149)
SMMHC-Cre Vascular smooth muscle(142,149)
NG2-Cre Arteriolar pericyte(214)
FoxD1-Cre Pericyte/connective tissue interstitium(153)
Vav1-Cre Hematopoietic cells and endothelium(149)
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FOP.(172) Additionally, the c-kit tyrosine kinase inhibitor Imatinib
induces mast cell apoptosis, and Imatinib treatment was
observed to decrease HO in an Achilles tenotomy model of
traumatic HO in mice.(82) Interestingly, there is some evidence
that mast cells and macrophages may in some circumstances
synergize to induce HO formation.(169) Methods to deplete both
macrophages and mast cells reduced HO formation in the Acvr1
R206H knock-in mouse model greater than depletion of either
cell population alone.(169)
Adaptive immunity and HO
Like the innate immune system, the adaptive immune system
seems to play a role in HO genesis and/or propagation. The precise
mechanisms are not well understood. Lymphocytic inflammation
has been described as a common histologic feature of HO,(161)
particularly perivascular lymphocytic inflammation as a consistent
feature in peri-articular, nongenetic human HO.(76) In HO
associated with cardiac valves, a polyclonal chronic inflammatory
infiltrate is a common finding including lymphocytes, mast cells,
and plasma cells.(173,174) Likewise, lymphocyte accumulation has
been reported in the early stages of FOP lesions.(29) Several lines of
clinical or experimental evidence suggest that modulating
lymphocytic inflammation may reduce HO genesis. For example,
immunocompromised Rag1 mice (which lack B and T lympho-
cytes) demonstrate reduced HO formation after trauma.(175)
Likewise, corticosteroids inhibit experimental models of HO in
mice.(135) As previously mentioned, immunosuppressive cortico-
steroids are used clinically in FOP during flare-ups to reduce HO
formation.(24,176) There is also evidence that preoperative
radiation in patients undergoing hip arthroplasty may change
the inflammatory milieu of the area, thereby decreasing HO
formation.(177) Here, a study of hematoma fluid from patients
undergoing total hip arthroplasty found that patients who had
received preoperative radiation as HO prophylaxis had decreased
numbers of T regulatory cells, increased frequency of cytotoxic
T cells, as well as alterations in B-cell maturation.(177)
Inflammatory cytokines
A number of studies have demonstrated altered levels of
inflammatory cytokines associated with HO formation, both at a
wound site or systemically. Most data suggest a positive
correlation between increased inflammatory cytokines and HO
formation. These data associate the degree of inflammatory
response with the likelihood of HO genesis and may be used in
the future in a predictive/diagnostic fashion. Correlation of
levels of inflammatory cytokines to bone formation is best
documented in nongenetic HO. For example, in a mouse model
combining cutaneous burn with Achilles tenotomy, increased
serum levels of TNFa, IL-1b, IL-6, and MCP-1 were associated
with HO formation.(178) Local wound site expression of these
markers as assessed by qPCR was generally found to temporally
overlap with rise and fall of detected levels within the serum.(178)
Within the same model, increased levels of MCP-1 were also
found in murine saliva, although other assayed markers were too
low for detection.(178) Increased inflammatory markers have
also been observed among human traumatic HO, both at the
local and systemic level. For example, patients with penetrating,
high-energy extremity battle wounds demonstrated increased
levels of several cytokines and chemokines that were individu-
ally associated with HO genesis.(179) Specifically, serum IL-6,
IL-10, and MCP-1 and wound effluent IP-10 and MIP-1a were
positively associated with HO formation.(179) A similar study
found that among combat-associated high-energy trauma,
incidence of HO formation was associated with increased serum
and wound effluent IL-3.(180) Conversely, serum IL-12p70 and
wound effluent IL-13 in these patients were associated with a
reduced likelihood of HO.(180) It should also be noted that these
clinical studies used a panel of 24 inflammatory cytokines and
chemokines, and most did not correlate with HO incidence.
The correlation between inflammatory biomarkers and HO
formation in FOP is less clear. In a case-control study, the serum
of 15 FOP patients was compared with 25 relatives to determine
if increased tone of pro-inflammatory cytokines could be
detected.(181) No statistically significant differences were found
across 27 cytokines. However, two patients were reporting flare-
ups at the time of the sample collection and did trend toward
higher G-CSF and TNF-alpha levels within their serum.(181) In a
genetic mouse model of HO (Nfatc1-Cre/caAcvr1fl/wt, NFAT),
transgenic mice demonstrated a mixed picture of systemic
inflammatory markers.(178) For example, some markers such as
MCP-1 showed increased levels of expression in both serum and
saliva among transgenic animals compared with littermate
controls. Other markers, such as IL-1B or TNF-alpha, showed an
increase in saliva but not serum (or vice versa) among affected
animals.(178) The potential use of salivary biomarkers is an
important question in FOP, as the minor trauma of a blood draw
can trigger flare-ups and HO.
Several major limitations exist in the evaluation of inflamma-
tory cytokines. In the case, of traumatic HO, these patients
represent complex clinical scenarios, often with multi-system
trauma who receive complex resuscitative, medical, and surgical
interventions. As suggested in longitudinal assessments of the
same patient, inflammatory cytokine content may vary widely
with time. Moreover, from both mouse and human studies, it is
clear that inflammatory cytokine content differs based on fluid
analyzed (wound effluent, serum, or saliva), and even from the
same patient at the same time these metrics do not always
coincide. With these limitations considered, inflammatory
cytokine studies in mouse and human suggest that increased
local and systemic inflammation is associated with HO.
Trauma and inflammation
Traumatic injuries as well as burn and blast injuries are well-
characterized causes of increased systemic inflammation and
predisposing factors to HO formation. These associations have
been confirmed experimentally. One study to demonstrate this
effect showed greater heterotopic bone formation when
adipose-derived stem/stromal cells were implanted in mice
subjected to 30% body surface area burns.(78) Conversely,
traumatic HO has been reduced in experimental models by the
application of apyrase at the injury site, which causes ATP
hydrolysis and thereby reducing inflammation.(182) Another
study demonstrated that traumatic HO formation can be
mitigated by the administration of rapamycin, which inhibits
mTOR signaling and thereby alters the production of a number
of inflammatory signals among other changes.(183) Interestingly,
targeting mTOR was also demonstrated to be effective in
preventing HO formation in an FOP model.(184)
Neuroinflammation
As previously mentioned, CNS injury is a risk factor for HO
genesis. The pathoetiologic links between the central and
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peripheral nervous systems and HO formation are not yet clear
and likely are multifaceted. In animal models of FOP, blocking
the sensory nerve pathway appears to decrease HO forma-
tion.(176) As such, studies have examined the role of neuro-
inflammatory factors in HO formation, which may be dysregu-
lated in trauma. Substance P has been observed to be increased
in the lesions of both patients with FOP and with acquired
HO.(185) In a murine model of Achilles tendon HO formation,
substance P delivery alone promoted HO formation and
increased expression of BMP2; the addition of calcitonin
gene-related peptide (CGRP) in conjunction with substance P
mitigated this effect. CGRP alone had little effect.(186) Mast cells
are recruited by sensory neurons by signaling factors such as
substance P and have been strongly implicated in HO formation.
When mast cell degranulation is prevented, less HO formation
occurs.(167) In a study of neurogenic HO, investigators have
found substance P was elevated in the serum of neurogenic HO
patients and that serum from neurogenic HO mice induced
mesenchymal progenitor cells to undergo osteogenic differen-
tiation in vitro.(100) However, substance P is transient, and
studies have not shown continued expression beyond the
inflammatory phase of HO.
Signaling pathways in HO
The exact signaling pathways responsible for HO formation have
not been elucidated. Discussed below are several interacting
pathways that have been identified as significant in this process.
BMP signaling
In 1965, Marshall R Urist discovered a substance in the
extracellular bone matrix that had the ability to induce
heterotopic bone when implanted in soft tissue.(187) Since this
time, BMPs have been implicated to have central roles in bone
formation, bone repair, and HO. In fact, experimental models of
HO often rely on application of recombinant BMP protein(140,142)
or aberrant BMP2 or BMP4 overexpression.(142,146,188) Models of
trauma-induced HO have observed increased BMP signaling,
and BMP antagonism has reduced HO expanse in experimental
models.(135,189) Although there is no single unifying signaling
pathway responsible for both FOP and traumatic HO, the BMP
pathway is important in both processes.(94)
As discussed, FOP is caused by mutations in the ACVR1 gene,
which is thought to cause constitutive activation of the BMP
type 1 receptor ALK2.(135) Pathological activation of ACVR1 leads
to overactivation of the BMP cascade. These studies have begun
to change the thought of FOP as a process dependent on BMP
ligands to one dependent on Activin A ligands. Supporting this
observation, global expression of the R206H ALK2 receptor in
animal models results in elevated levels of Smad 1/5/8 and in
utero lethality.(190) Evidence suggests that Activin A also plays a
role in regulating innate immune cells and promoting the
development of mast cells that are involved in the development
of FOP lesions.(176) Activin A neutralizing antibodies have shown
remarkable inhibitory effects in FOP animal models.(191)
Ongoing clinical studies using an Activin A antibody offer
hope to those living with FOP, although they are not likely to
demonstrate efficacy in other forms of HO other than FOP.
Mammalian target of rapamycin (mTOR)
The mTOR signaling pathway regulates numerous cellular
processes, including chondrogenic differentiation(192) (see (193)
for a review). Using cells from patients with FOP, aberrant Activin
A signaling via the mutated ACVR1 receptor has been shown to
increase mTOR signaling.(184) Moreover, rapamycin has been
shown to suppress HO formation in experimental FOP
models.(151,184) In addition, administration of rapamycin inhibits
experimental models of trauma-induced HO formation.(151,183)
The effect of the mTOR pathway in promoting HO formation
appears to be augmented by leptin; in both in vitro studies on
tendon-derived stem cells and a rat model of traumatic HO
formation via Achilles tenotomy, leptin promoted osteogenesis,
and this effect was mitigated in the presence of rapamycin.(194)
Hypoxia-inducible factors (HIFs)
HIFs activate genes encoding proteins that mediate adaptive
response to reduced oxygen tension (see Laplante and
Sabatini(195) for a review). The HIF complex consists of 1 of 3
a subunits bound to HIFß. The HIFa pathway couples bone and
vascular growth during development.(196) Relative tissue
hypoxia causes HIF1a activation, which increases production
of pro-angiogenic cytokines such as VEGF.(155,197,198) Both
experimental models of traumatic HO and FOP-like HO
demonstrate hypoxia and increased HIF1a signaling.(151) FOP
samples from human patients likewise show increased HIF1a
immunostaining.(199) Moreover, pharmacologic inhibition of
HIF1a attenuates HO formation across experimental models of
HO.(151,199) These results have been confirmed via alternative
techniques, including gene silencing(200) and genetic
ablation.(199)
Retinoic acid receptor (RAR) signaling
Retinoids are potent morphogens, impacting both osteogenesis
and chondrogenesis, to impact skeletal development.(201) There
are two classes of nuclear receptors, the retinoic acid receptors
(RAR a, ß, and g) and the retinoid x receptors (RXR a, ß, and g).
These receptors bind as RAR/RXR heterodimers or RXR
homodimers to the DNA motifs called RA-response elements
(RAREs) to activate transcription of RA target genes.(202)
Unliganded receptors have also been recognized as having
equally important function of actively repressing target gene
repression through the recruitment of nuclear corepressors and
associated histone deacetylases (HDACs).(202,203) With regard to
limb skeletal development, RARa is expressed throughout the
limb mesenchyme early in limb development. As cells begin to
differentiate into chondrocytes, RARa is downregulated,
remaining highly expressed in the perichondrium, whereas
RARg expression becomes localized in the cartilaginous
elements.(203,204)
It was previously demonstrated that the continued expression
of RARa in prechondrogenic cells prevents their differentiation,
resulting in skeletal developmental malformations in transgenic
mice,(205) leading to the idea that RARa agonism could impede
HO formation. A selective RARa agonist was first tested in a
subcutaneous rBMP2-induced HO model in mice.(206) Reduced
amounts of heterotopic cartilage and bone were found, yet
complete abrogation of HO was not found.(125,206) Follow-up
studies examined the effect of both RARa and RARg ago-
nists.(125) RARg agonists were observed to abrogate rBMP2-
induced subcutaneous and intramuscular HO, as well as
dramatically reduce ossification in the ALK2Q207D mouse
model.(125) Both agonists for RARa and RARg inhibited chondro-
genesis and prevented HO, but RARg agonists were more
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effective.(134) The higher efficacy of RARg agonists may be
explained by a wider expression pattern of RARg in both
chondrogenic cells and chondrocytes compared with RARa
and RARß.(125,134) Mechanistically, RARg agonists have been
observed to dampen BMP signaling, both by inhibition of Smad
phosphorylation and by a significant proteasome-mediated
drop in overall Smad levels.(125) Palovarotene, a specific RARg
agonist (which was previously tested in a clinical trial for
emphysema) was shown to counteract multiple soft tissue and
skeletal pathologies in Acvr1R206H/þ mutant mice. In their
damaged muscle tissue, Palovarotene was associated with fewer
mast cells and reductions in fibroproliferation, cartilage forma-
tion, and the amount of HO.(134) Recent studies in animal models
have suggested potential off-target effects of RARg agonist
treatment, including skeletal abnormalities and delayed wound
healing.(207,208) Nevertheless, ongoing clinical trials of the RARg
agonist Palovarotene have shown potential for the treatment of
FOP.(209) Palovarotene is currently being studied in a phase 3
clinical trial.(210)
GNAS
GNAS is a complex imprinted gene of the alpha-subunit of the
stimulatory heterotrimeric G protein (GaS). As a key regulator in
skeletal development, GaS inhibits hedgehog (Hh) signaling
and loss of GNAS results in aberrant Hh signaling activation.(211)
As previously discussed, inactivating mutations within the
GNAS gene results in either Albright’s hereditary osteodys-
trophy (AHO) or POH (progressive osseous heteroplasia). HO
formation resembling POH has been replicated experimentally
in mouse models using several Cre lines, including Prx1-Cre,
Dermo1-Cre, and Ap2a-Cre.(211) In these animal models and in
POH human samples, Hedgehog signaling activity is increased.
Moreover, Hh signaling pathway inhibition, either by genetic or
chemical approaches, reduced HO formation in this animal
model.(211) Somewhat analogous findings regarding the
presence of Hh signaling activation have been observed in
predominantly endochondral HO mouse models as well.(212)
For example, in a BMP4 overexpression model of mouse
model of HO, Gli1-expressing cells (using the Gl1-CreERT
reporter system) were found to contribute to all stages of
endochondral HO.(212)
Summary
In summary, heterotopic ossification is a diverse pathologic
process, with different etiologies, tissue locations, mechanisms
of ossification, and putative cell types of origin. Uniting this
diversity of HO are key commonalities, including the phasic
nature of the disease process that often arises in a background of
inflammation with or without tissue trauma. Those susceptibility
factors that predict which patients and what injury types will
progress to HO formation are not well defined. The extent to
which inflammatory cascades can be manipulated to prevent
HO formation is only beginning to be understood. Moreover,
current prophylactic or treatment strategies have significant
shortcomings. These gaps in our knowledge require further
study of this distinctive and understudied condition.
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